This database contains 14 studies, archived under the term: "risperidone"
Click here to filter this large number of results.
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan,
Sultzer, David,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Andrews, Howard,
Levin, Bruce
Objectives: : Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients […]
Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease
Mohamed, Somaia,
Rosenheck, Robert,
Lyketsos, Constantine G.,
Kaczynski, Richard,
Sultzer, David L.,
Schneider, Lon S.
Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]
Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial
Culo, Sandi,
Mulsant, Benoit H.,
Rosen, Jules,
Mazumdar, Sati,
Blakesley, Richard E.,
Houck, Patricia R.,
Pollock, Bruce G.
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and […]
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD
Vigen, Cheryl L. P.,
Mack, Wendy J.,
Keefe, Richard S. E.,
Sano, Mary,
Sultzer, David L.,
Stroup, T. Scott,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Tariot, Pierre N.,
Zheng, Ling,
Schneider, Lon S.
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer’s disease trial
Wessels, Alette M.,
Pollock, Bruce G.,
Anyama, Norbert G.,
Schneider, Lon S.,
Lieberman, Jeffrey A.,
Marder, Stephen R.,
Bies, Robert R.
Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer’s disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer’s Disease Trial that […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study
Zheng, Ling,
Mack, Wendy J.,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Stroup, T. Scott,
Sultzer, David L.,
Tariot, Pierre N.,
Vigen, Cheryl,
Schneider, Lon S.
Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) […]
Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer’s disease: a 3-year follow-up longitudinal study
Angelucci, Francesco,
Bernardini, Sergio,
Gravina, Paolo,
Bellincampi, Lorenza,
Trequattrini, Alberto,
Di Iulio, Fulvia,
Vanni, Diego,
Federici, Giorgio,
Caltagirone, Carlo,
Bossù, Paola,
Spalletta, Gianfranco
Although the etiology of psychotic symptoms (hallucinations and delusions) in Alzheimer’s disease is still not known, alterations in serotonergic neurotransmission have been proposed. In a 3-year follow-up study, we evaluated the association of serotonin (5-HT) receptor 5-HT2a 102T/C polymorphism (allelic variants CC, CT and TT) with psychotic symptom severity and response to treatment with atypical […]
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
Marras, Connie,
Herrmann, Nathan,
Anderson, Geoffrey M.,
Fischer, Hadas D.,
Wang, Xuesong,
Rochon, Paula A.
Background: Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.; Objective: We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or […]